IRCT20200711048078N1 IRCT 2020-08-27 Tehran University of Medical Sciences Effect Evaluation of Melatonin in treatment of Polycystic Ovarian Syndrome Comparing the Effect of Melatonin with Placebo in Combination with Medroxy Progesterone in Women with Polycystic Ovarian Syndrome 2020-10-29 anticipated 88 Complete https://irct.ir/trial/49565 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted Block Randomization: Random division is done in the form of "blocks" with a predetermined size and the number of people is evenly distributed among the study groups. Randomization unit: individual Randomization Tools: Statistical Software, Blinding description: The process of research will be explained to the patients and a consent form will be obtained from them, but we do not inform them which group they belong to. In this research, the researcher and the advisor are clinical caregivers who do not know which patient is taking the drug and which is taking a placebo by using the coding method. The only person who knows what group each patient belongs to is the supervisor who knows the coding. 2 Polycystic ovarian syndrome. Intervention 1: Intervention group: For 12 weeks, in addition to receiving basic treatment (from day 16 of the cycle for two weeks, 10 mg of medroxyprogesterone per night), she takes 6 mg of melatonin daily, as well as at night before bedtime. Intervention 2: Control group: For 12 weeks, in addition to receiving basic treatment (from day 16 of the cycle for two weeks, 10 mg of medroxyprogesterone per night), she takes placebo daily, as well as at night before bedtime. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information.